Validation of the Telephone Interview for Cognitive Status-modified in Subjects with Normal Cognition, Mild Cognitive Impairment, or Dementia

Department of Neurology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Neuroepidemiology (Impact Factor: 2.56). 11/2009; 34(1):34-42. DOI: 10.1159/000255464
Source: PubMed


The telephone assessment of cognitive functions may reduce the cost and burden of epidemiological studies.
We validated the Telephone Interview for Cognitive Status-modified (TICS-m) using an extensive in-person assessment as the standard for comparison. Clinical diagnoses of normal cognition, mild cognitive impairment (MCI), or dementia were established by consensus of physician, nurse, and neuropsychological assessments.
The extensive in-person assessment classified 83 persons with normal cognition, 42 persons with MCI, and 42 persons with dementia. There was considerable overlap in TICS-m scores among the three groups. Receiver operating characteristic curves identified < or = 31 as the optimal cutoff score to separate subjects with MCI from subjects with normal cognition (sensitivity = 71.4%; subjects with dementia excluded), and < or = 27 to separate subjects with dementia from subjects with MCI (sensitivity = 69.0%; subjects with normal cognition excluded). The TICS-m performed well when subjects with MCI were pooled either with subjects with dementia (sensitivity = 83.3%) or with subjects with normal cognition (sensitivity = 83.3%).
Although the TICS-m performed well when using a dichotomous classification of cognitive status, it performed only fairly in separating MCI from either normal cognition or dementia. The TICS-m should not be used as a free-standing tool to identify subjects with MCI, and it should be used with caution as a tool to detect dementia.

13 Reads
  • Source
    • "79% females ), a subset from a larger trial evaluating stressreducing aromatherapy effects (clinical trial ID number NCT01307748), were recruited from the community through advertisements. Eligibility criteria were assessed by a phone interview and included (1) age between 50 and 85 years; (2) good physical and cognitive health (score ≥31 on the Modified Telephone Interview for Cognitive Status [28]); (3) score ≥9 on the Perceived Stress Scale [29] indicating presence of stress; (4) no medications affecting CNS or physiologic measures; (5) healthy olfactory function; and (6) nonsmoking. The study was approved by the Oregon Health & Science University Institutional Review Board. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective. Stress-reducing therapies help maintain cognitive performance during stress. Aromatherapy is popular for stress reduction, but its effectiveness and mechanism are unclear. This study examined stress-reducing effects of aromatherapy on cognitive function using the go/no-go (GNG) task performance and event related potentials (ERP) components sensitive to stress. The study also assessed the importance of expectancy in aromatherapy actions. Methods. 81 adults were randomized to 3 aroma groups (active experimental, detectable, and undetectable placebo) and 2 prime subgroups (prime suggesting stress-reducing aroma effects or no-prime). GNG performance, ERPs, subjective expected aroma effects, and stress ratings were assessed at baseline and poststress. Results. No specific aroma effects on stress or cognition were observed. However, regardless of experienced aroma, people receiving a prime displayed faster poststress median reaction times than those receiving no prime. A significant interaction for N200 amplitude indicated divergent ERP patterns between baseline and poststress for go and no-go stimuli depending on the prime subgroup. Furthermore, trends for beneficial prime effects were shown on poststress no-go N200/P300 latencies and N200 amplitude. Conclusion. While there were no aroma-specific effects on stress or cognition, these results highlight the role of expectancy for poststress response inhibition and attention.
    Evidence-based Complementary and Alternative Medicine 01/2015; 2015:1-10. DOI:10.1155/2015/419812 · 1.88 Impact Factor
  • Source
    • "Returned screening questionnaires will be immediately scanned and volunteers deemed potentially eligible will be contacted within 2 weeks to organise a telephone interview for the assessment of cognitive function (TICSm) [35] and, for those free of cognitive impairment, an assessment of current and past mental state with the SCID-I, which is a structured clinical interview for axis I diagnoses that can be administered by trained research staff over the telephone [36]. It provides reliable and valid information to establish the diagnosis of major depressive episode (recurrent or single episode) according to DSM-IV-TR criteria [37] (which is consistent with DSM-5 criteria). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Depression is a leading cause of disability worldwide and, although efficacious treatments are available, their efficacy is suboptimal and recurrence of symptoms is common. Effective preventive strategies could reduce disability and the long term social and health complications associated with the disorder, but current options are limited. Cognitive bias modification (CBM) is a novel, simple, and safe intervention that addresses attentional and interpretive biases associated with anxiety, dysphoria, and depression. The primary aim of this trial is to determine if CBM decreases the one-year onset of a major depressive episode among adults with subsyndromal depression. Design and methods This randomised controlled trial will recruit 532 adults with subsyndromal symptoms of depression living in the Australian community (parallel design, 1:1 allocation ratio). Participants will be free of clinically significant symptoms of depression and of psychotic disorders, sensory and cognitive impairment, and risky alcohol use. The CBM intervention will target attentional and interpretive biases associated with depressive symptoms. The sessions will be delivered via the internet over a period of 52 weeks. The primary outcome of interest is the onset of a major depressive episode according the DSM-IV-TR criteria over a 12-month period. Secondary outcomes of interest include change in the severity of depressive symptoms as measured by the Patient Health Questionnaire (PHQ-9), use of antidepressants or benzodiazepines, and changes in attention and interpretive biases. The assessment of outcomes will take place 3, 6, 9, and 12 months after randomisation and will occur via the internet. Discussion We propose to test the efficacy of an innovative intervention that is well grounded in theory and for which increasing empirical evidence for an effect on mood is available. The intervention is simple, inexpensive, easy to access, and could be easily rolled out into practice if our findings confirm a role for CBM in the prevention of depression. Trial registration Australian and New Zealand Clinical Trials Registry ACTRN12613001334796. Date: 5th December 2013.
    Trials 07/2014; 15(1):282. DOI:10.1186/1745-6215-15-282 · 1.73 Impact Factor
  • Source
    • "We excluded participants who did not answer the telephone interview themselves (n = 185) and those with cognitive impairment (n = 146) as determined with TICS-m (Telephone interview for cognitive status – modified) (Breitner & Welsh 1995; Crooks et al. 2005; Perneczky 2003) using a cut off value of 27 (Knopman et al. 2010). Eighty-four participants with missing values on the resilience scale were excluded. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to assess reliability and validity of the Resilience Scale 11 (RS-11) and develop a shorter scale in a population-based study. The RS-11 scale was administered to 3942 participants (aged 64 - 94 years) of the KORA-Age study. To test reliability, factor analyses were carried out and internal consistency (Cronbach's α) was measured. Construct validity was measured by correlating scores with psychological constructs. The criterion for a shorter scale was a minimum internal consistency of .80. Shorter models were compared using confirmatory factor analysis. Sensitivity and specificity of RS-5 to RS-11 was analyzed. Factor analysis of the RS-11 gave a 1-factor solution. Internal consistency was α = .86. A shorter version of the scale was developed with 5 items, which also gave a 1-factor solution and showed good validity. Internal consistency of this shorter scale: Resilience Scale 5 (RS-5) was α = .80. Sensitivity and specificity of RS-5 compared with RS-11 were .79 and .91 respectively. Both scales correlated significantly in expected directions with related constructs. The RS-11 and the RS-5 are reliable, consistent and valid instruments to measure the ability of elderly individuals to successfully cope with change and misfortune.
    11/2013; 1(1). DOI:10.1186/2050-7283-1-25
Show more


13 Reads
Available from